1 / 64

Progesterone Supplementation and Prevention of Preterm Birth

Progesterone Supplementation and Prevention of Preterm Birth. Catherine Y Spong, MD Chief, Pregnancy & Perinatology Branch National Institute of Child Health & Human Development National Institutes of Health. Conflict of Interest Statement.

griffin-le
Download Presentation

Progesterone Supplementation and Prevention of Preterm Birth

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Progesterone Supplementation and Prevention of Preterm Birth Catherine Y Spong, MD Chief, Pregnancy & Perinatology Branch National Institute of Child Health & Human Development National Institutes of Health

  2. Conflict of Interest Statement • I have no conflict of interest related to the content of this presentation

  3. Objectives • to describe the problem of prematurity • to describe the mechanism of progesterone action • to define the patient population who meets the criteria for progesterone administration to prevent preterm birth

  4. Preterm Delivery: A Public Health Priority • 1 in 8 infants is born preterm • 542,893 preterm births each year (2006) • leading cause of hospitalization among pregnant women • leading cause of death among African-American infants • associated with developmental disabilities

  5. Leading Causes of Neonatal Mortality, 2001 (N / 100,000 live births) 4,322 3,875 1,491 998 • Leading cause of black infant mortality • Second leading cause of all infant mortality 943 http://www.cdc.gov/nchs/data/nvsr/nvsr52/nvsr52_09.pdf Table H. Deaths and percentage of total deaths for the 10 leading causes of neonatal and postneonatal deaths: United States, 2001

  6. Preterm Birth: Outcome • 1 out of 5 children with mental retardation • 1 out of 3 children with vision impairment • Almost half of children with cerebral palsy Accounts for

  7. Preterm Birth: Long Term Outcome • For the baby: • Increased risk for cardiovascular disease (MI, stroke, hypertension) as an adult • Increased risk for diabetes as an adult • Possible increase in cancer risk • For the mother: • Increased risk for subsequent preterm delivery Birth Weight and Coronary Heart Disease Lower BW=higher CHD risk Age Adjusted Relative Risk Birthweight (lbs) Rich-Edwards 1997

  8. Progestins • Steroid hormone • Exogenous or synthetic forms of progesterone • Produced by corpus luteum, adrenals, placenta • Maintains pregnancy • Exerts biologic effects on • Immune response • Myometrium • Chorioamniotic membranes • Cervix

  9. Actions • Delays cervical collagen degradation • Myometrial: • Decreases conduction of contractions • Increases threshold for stimulation • Decreases spontaneous activity • Decreases number of oxytocin receptors • Prevents formation of gap junctions

  10. Progestin formulations • 17ahydroxyprogesteronecaproate • Esterified derivative of 17a hydroxyprogesterone • Substantial progestational activity, long duration of action • Micronized progesterone in a gel • Micronized progesterone suppositories

  11. Trials of Progestogens • Results of several small trials in the 1960’s and 1970’s suggested progesterone therapy may be effective in preventing preterm birth • Not all trials showed positive results • Meta-analyses produced conflicting results • The most successful trials employed 17-a Hydroxyprogesterone Caproate, (17P)

  12. Meta-analysis of 17P in pregnancy • 5 trials: high risk women with 17P • Pooled analysis of results showed: • Reduction in rates of preterm birth Odds ratio 0.50, 95% CI: 0.30-0.85 • Reduction in rates of low birthweight Odds ratio 0.46, 95% CI: 0.27-0.80 Keirse MJNC. Brit J Obstet Gynecol 1990;97:149

  13. Prior preterm birth Multifetal gestation Preterm birth Progestins & Prematurity Prevention Short cervix

  14. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study • University of Sao Paulo Medical School, Brazil • RCT double-blind, placebo controlled • 1996-2001 • Rx: daily Progesterone (100 mg) vs placebo as vaginal suppository from 24 – 34 wks Da Fonseca et al AJOG 2003;188:419-24

  15. Methods • 157 high risk singleton pregnancies, 15(9.5%) lost to follow-up; • Prior sPTD (avg 33 wks) • Prophylactic cervical cerclage • Uterine malformation • Analyzed remaining 142 • 70 placebo • 72 progesterone Da Fonseca et al AJOG 2003;188:419-24

  16. Characteristics Prog Placebo • Qualifying delivery (wks) 33.3 33.4 • Maternal age (yrs) 27.6 26.8 • Caucasian 68% 71% • Risk Factor • Prior PTD 90% 97% • Uterine malformation 5.6% 1.4% • Incompetent cervix 4.1% 1.4% Da Fonseca et al AJOG 2003;188:419-24

  17. Rates of Preterm Birth Placebo Placebo Prog Placebo Prog Prog P<0.002 P<0.03 NS Da Fonseca et al AJOG 2003;188:419-24

  18. Uterine contraction frequency1 hr monitoring/wk Placebo Progesterone UC/hr P<0.004 Gestational age (wk) Da Fonseca et al AJOG 2003;188:419-24

  19. NICHD: MFMU Progesterone Trial • Aim: To establish if weekly progesterone injections in women with prior spontaneous preterm delivery (sPTD) reduces the risk of PTD • Design: double-masked, placebo-controlled trial • Eligibility criteria: singleton pregnancy 16-20 wks with documented previous sPTD • Intervention: progesterone or placebo • 1o outcome: delivery <37 wks • Sample: 463 pregnant women Meis et al, N Engl J Med 2003

  20. 19 Centers enrolled women with: • Documented history of spontaneous preterm birth at 200 to 366 weeks’ gestation in a previous pregnancy • Gestational age at entry of 15-203 weeks confirmed by ultrasound • Singleton gestation, with no major fetal anomalies Meis et al, N Engl J Med 2003

  21. Characteristics 17-P Placebo • Qualifying delivery (wks) 30.5 31.3 • Maternal age (yrs) 26.0 26.5 • Married 51% 46% • African American 59% 58% • Mean BMI 26.9 25.9 • Smoking 22% 19%

  22. Progesterone: Rates of Preterm Birth 17P 17P 17P 17P 17P African American Non African American P<0.0001 P<0.016 P<0.018 P=0.010 P=0.004 Meis et al, N Engl J Med 2003 Meis et al, N Engl J Med 2003

  23. Progesterone prevents neonatal complications Placebo 17 P Placebo Placebo Placebo 17 P Placebo 17 P 17 P Meis et al, N Engl J Med 2003 Meis et al, N Engl J Med 2003

  24. Compliance and Side Effects • Compliance with the weekly injections was excellent • 91.5% of the women received their injections at the scheduled time • Side effects were minor and were similar in the 17P and placebo groups

  25. Effectiveness of Progesterone • 5-6 women with a previous sPTB would need to be treated to prevent one birth <37 wks • 12 women with a previous sPTB birth would need to be treated to prevent one birth <32 wks Low dose ASA to prevent CVA, NNT=102 B-blocker use in MI patients to prevent cardiac death NNT=42 Meis et al, N Engl J Med 2003 Meis et al, N Engl J Med 2003

  26. Progesterone prevents recurrent preterm delivery • Weekly injections of progesterone prevented recurrent preterm birth and improved the neonatal outcome for pregnancies at risk • Effective in preventing very early as well as later preterm birth • Effective in both African American and Non-African American women Meis et al, N Engl J Med 2003 Meis et al, N Engl J Med 2003

  27. Impact of progesterone to prevent recurrent preterm birth • 10,000 preterm births could have been prevented in 2002 if all eligible pregnant women at high risk for PTD received 17P • Resulting in reduction of preterm birth of ~2% Petrini et al, Obstet Gynecol 2005; 105(2)

  28. Progesterone gel and PTD • 659 women with prior sPTB • GA 18-22.9 wks, randomized • Progesterone vaginal gel or placebo • 90mg natural progesterone (Replens) • Primary outcome: PTB<32 wks O’Brien et al, Ultrasound Obstet Gynecol 2007;30:687-96

  29. Characteristics Prog Placebo • Maternal age (yrs) 27.1 27.3 • African American 25% 28% • Mean BMI 26.6 26.4 • Smoking 22% 19% • >1 Prior PTD 24% 26% • CL at randomization 3.7 3.7 O’Brien et al, Ultrasound Obstet Gynecol 2007;30:687-96

  30. Vaginal progesterone gel and PTD % O’Brien et al, Ultrasound Obstet Gynecol 2007;30:687-96

  31. Summary: Progesterone & recurrent PTD • progesterone suppository & 17aOHPC IM: Significant reductions in PTD • Progesterone gel: no effect on PTD progesterone PTD 17P 17P

  32. Prior preterm birth Multifetal gestation Preterm birth Progestins & Prematurity Prevention Short cervix

  33. STTARS Seventeen alpha-hydroxyprogesterone caproate in Twins and Triplets: A Randomized Study) • Double-masked placebo-controlled trial to determine whether 17 a hydroxyprogesterone prevents preterm birth in multifetal pregnancies. • Intervention: 17-OHPC (250mg IM) or placebo weekly beginning at 16-20 weeks • Primary outcome: Preterm delivery < 35 wks • 661 women randomized Rouse et al, NEJM 2007; 357:454-61

  34. Progesterone and Twins Characteristics: Prog Placebo • Maternal age (yrs)30 30 • Caucasian 67% 65% • Ob history • Nulliparous 46% 43% • Prior PTD 6% 9% • BMI 26.7 27.1 Rouse et al, NEJM 2007; 357:454-61

  35. Twins: Delivery or Fetal Death Prior to 37, 35, 32 or 28 weeks 17-OHPC Placebo Similar findings for triplets Rouse et al, NEJM 2007; 357:454-61

  36. Delivery or Fetal Death Before 35 WeeksBy Conception Method & Chorionicity Similar findings for triplets Rouse et al, NEJM 2007; 357:454-61

  37. STTARS Seventeen alpha-hydroxyprogesterone caproate in Twins and Triplets: A Randomized Study) • 17P did not reduce the rate of PTB in women with twins • This lack of benefit applied: - whether conception was spontaneous or after ART or - whether there was a di- or monochorionic placentation - regardless of gestational age cutoff • 17-OHPC was well tolerated with side effects limited to the injection site • The rate of PTB in the placebo group was similar to national norms (34.9 vs 35.2 weeks) Rouse et al, NEJM 2007; 357:454-61

  38. Prior preterm birth Multifetal gestation Preterm birth Progestins & Prematurity Prevention Short cervix

  39. Cervical length Normal cervical length Short cervix with funneling

  40. Cervical length at 24 wks predicts PTB risk Relative risk of sPTD <35wks by % of cervical length at 24 wks Iams et al, NEJM 1996

  41. Considerations • Study population heterogeneity • Other risk factors for PTB • multiple gestation • prior preterm birth • Gestational age assessment of cervical length • Cervical length varies across gestational age • Cut-off selected depends on time of screening

  42. Cervical length assessment Fonseca 20-25 <37 weeks <15mm (1.7%) N=24,620

  43. Progesterone and short cervix: DeFrancosubanalysis of O’Brien trial: progesterone gel • 46 women with ≤ 28 mm cervical length • 19 progesterone (4 without PTB + 15 with PTB) • 27 placebo (5 without PTB + 22 with PTB) % “…these conclusions must be considered tentative...(and) hypothesis generating… (and)… further investigation is necessary. Specifically randomized clinical trials designed to test the effect of progesterone in women with a short cervix…” DeFranco et al, Ultrasound Obstet Gynecol 2007;30:697-705

  44. Progesterone and short cervix: Fonseca trial: progesterone suppository • Cervical length 20-25 wks (24,620 women) • 413 CL <15mm (1.7%) • RCT: 250 women with cervical length ≤ 15mm • Progesterone 200 mg* PV daily vs. placebo • Micronized progesterone (Utrogestan, Besins International Belgium) • Initiation of treatment at 24 weeks *twice the dose of the daFonseca trial AJOG 2003 Fonseca et al, NEJM 2007; 357:462-9

  45. Progesterone and short cervix: Fonseca trial: progesterone suppository Prog Placebo • Maternal age (yrs)29 29 • Caucasian 37% 39% • Ob history • Nulliparous 57% 55% • Prior PTD 12% 18% • Twin gestation 9% 10% Fonseca et al, NEJM 2007; 357:462-9

  46. Progesterone and short cervix: Fonseca trial: progesterone suppository n=125 n=125 • Progesterone reduced risk of PTD in women with short cervix • No reduction in perinatal mortality or neonatal morbidity PTD<34 weeks Fonseca et al, NEJM 2007; 357:462-9

  47. Progesterone and short cervix: Fonseca trial: progesterone suppository

  48. Progesterone and short cervix: Fonseca trial: progesterone suppository • Very heterogeneous study group • Includes women with prior PTD, multiple gestations • Subgroup analysis of nulliparous women has OR that crosses unity

  49. 19 to 23 6/67 weeks Singleton Cervix 10-20 mm Nullips and multips (with prior term and preterm birth) Outcome: PTB < 33 weeks N = 465 Progesterone and short cervix: Hassan trial: progesterone gel Hassan et al, 2011 Ultrasound Obstet Gynecol

  50. Progesterone and short cervix: Hassan trial: progesterone gel *P < .05 PTB% * * Hassan et al, 2011 Ultrasound Obstet Gynecol

More Related